| Dr Anthony N Conti, DO | |
|
1211 Elm St, Reading, PA 19604-2927 | |
| (610) 371-7700 | |
| (610) 371-9189 |
| Full Name | Dr Anthony N Conti |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 1211 Elm St, Reading, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205007051 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | OS006006L (Pennsylvania) | Primary |
| Entity Name | Pennsylvania Department Of Human Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497739973 PECOS PAC ID: 0547168064 Enrollment ID: O20031222000595 |
News Archive
A BCI is an apparatus that allows an individual to control a machine or computer directly from their brain.Non-invasive means of control like electroencephalogram (EEG) readings taken through the skull are safe and convenient compared to more risky invasive methods using a brain implant, but they take longer to learn and users ultimately vary in proficiency.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.
Older adults who used the herbal supplement Ginkgo biloba for several years did not have a slower rate of cognitive decline compared to adults who received placebo, according to a study in the December 23/30 issue of JAMA.
Twenty-six percent (26%) of black Americans (BA) with chronic hepatitis C who received treatment with Pegasys plus Copegus (peginterferon alfa-2a plus ribavirin) achieved a sustained virological response (SVR), according to study results published in the June 2004 issue of Hepatology.
The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Anthony N Conti, DO 1211 Elm St, Reading, PA 19604-2927 Ph: (610) 371-7700 | Dr Anthony N Conti, DO 1211 Elm St, Reading, PA 19604-2927 Ph: (610) 371-7700 |
News Archive
A BCI is an apparatus that allows an individual to control a machine or computer directly from their brain.Non-invasive means of control like electroencephalogram (EEG) readings taken through the skull are safe and convenient compared to more risky invasive methods using a brain implant, but they take longer to learn and users ultimately vary in proficiency.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.
Older adults who used the herbal supplement Ginkgo biloba for several years did not have a slower rate of cognitive decline compared to adults who received placebo, according to a study in the December 23/30 issue of JAMA.
Twenty-six percent (26%) of black Americans (BA) with chronic hepatitis C who received treatment with Pegasys plus Copegus (peginterferon alfa-2a plus ribavirin) achieved a sustained virological response (SVR), according to study results published in the June 2004 issue of Hepatology.
The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.
› Verified 9 days ago
Dr. Gary David Zimmer, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 Bernville Rd, Reading, PA 19605 Phone: 215-710-5900 Fax: 866-789-6895 | |
David Curtis Wright, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 215 N 12th St, Reading, PA 19604 Phone: 610-371-7700 | |
George P Desjardins, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 215 N 12th St, Reading, PA 19604 Phone: 610-371-7700 | |
Neil Gulati, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: Sixth And Spruce Street, Reading, PA 19611 Phone: 610-988-8219 | |
Dr. Gregory J Owsik, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 6th Avenue And Spruce Street, Reading, PA 19611 Phone: 484-628-3637 | |
Alla Goldman, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 215 N 12th St, Reading, PA 19604 Phone: 610-371-7700 |